Roivant's IMVT-1402 Shows Positive Skin Trends in Lupus Study but Misses Primary Endpoint

Roivant Sciences (ROIV) reported mixed topline results from a proof-of-concept trial of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus, an autoimmune condition affecting the skin. The drug showed positive trends in some measures but failed to meet the study's main goal. The company disclosed the findings on September 23, 2026, without providing detailed efficacy statistics in the announcement. Cutaneous lupus is a chronic disease with limited treatment options, leaving a substantial unmet need. IMVT-1402 is being developed as a potential therapy across autoimmune indications. Investors had viewed the readout as a key catalyst for Roivant's pipeline. Shares of the company may face pressure given the primary endpoint miss, though the positive secondary signals could support further development.